Brief Title
Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy
Official Title
Exercise Study of Function and Pathology for Women With X-ALD
Brief Summary
The purpose is to see how X-linked adrenoleukodystrophy (X-ALD) is associated with strength
and sensation using MRI, in women with X-ALD. The investigators will also see whether
exercise can improve these symptoms for women with X-ALD.
Detailed Description
X-linked adrenoleukodystrophy (X-ALD), a [sex-linked] progressive neurodegenerative disease,
is caused by a defect in the ABCD1 gene. The disease is expressed in multiple ways, but the
most common adult form is adrenomyeloneuropathy (AMN), which results in slowly progressive
changes in muscle tone and weakness, sensory loss, and dysfunction of the autonomic nervous
system. In a previous study the investigators linked abnormalities in the [brain/spinal cord]
to lower extremity weakness in men with AMN; however, there have been no studies evaluating
these relationships in women carriers (i.e., women with AMN). It is unknown, in women with
AMN, how the pattern of damage in the brain and spinal cord relates to disability and if
these patterns predict responsiveness to treatment. The investigators hypothesize that by
using magnetization transfer (MT) and diffusion tensor imaging (DTI), two magnetic resonance
imaging (MRI) modalities, to track particular changes in the brain and spinal cord will
predict disability and additionally, who is likely to respond best to a training regimen. The
investigators expect that these more advanced imaging techniques will be more sensitive and
accurate quantitative measures of clinical motor function and women with greater loss in the
spinal cord compared to the brain will benefit most from training to improve disability. To
test this hypothesis, women with AMN will receive MRI scans at baseline and complete measures
of global walking and lower extremity impairments of vibration sensation, spasticity, and
strength at three time-points: baseline, 12 weeks, and 18 weeks after baseline. The group
will participate in a resistive training program for 12 weeks. MRI data will be correlated to
changes over time in measures of impairment to determine their relationships. The linking of
this information will not only be important for better defining disability in women with AMN
but it will also help to guide physicians and rehabilitation therapists in predicting who is
likely to respond to rehabilitative interventions, as well as for optimizing the effects of
future pharmacological interventions.
Study Type
Interventional
Primary Outcome
Change in Maximal Voluntary Contraction of the Hip Flexors From Baseline to End of Training and to Post-training
Condition
X-linked Adrenoleukodystrophy
Intervention
exercise training
Study Arms / Comparison Groups
exercise
Description: Female carriers as well as healthy age and gender matched individuals will participate in an exercise paradigm.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Behavioral
Estimated Enrollment
31
Start Date
May 2012
Completion Date
October 2014
Primary Completion Date
October 2014
Eligibility Criteria
Inclusion Criteria:
- confirmed diagnosis, X-ALD heterozygote carrier
- no medical contraindication to participating in a strength training program
- able to follow complex directions as determined by a score of ≤1 on a subset of
questions taken from the NIH Stroke scale (Brott et al. 1989)
- hip flexion strength: 6.6-15.8kg
- hip extension strength: up to 18.3 kg
- normal passive range of motion at hips/knees/ankles
- able to walk ≥50m
Exclusion Criteria:
- Evidence of other neurological deficit that could interfere, such as previous stroke
or muscle disease
- congestive heart failure
- cancer
- orthopedic conditions
- severe pain that precludes study participation
- seizures
- pregnancy
- other medical condition that precludes participation in an exercise program, e.g.,
unstable angina, uncontrolled diabetes, uncontrolled hypertension
Healthy controls have the same age and exclusion criteria as women with AMN except that
they will not be carriers for X-ALD. They must have normal neurological function.
Gender
Female
Ages
21 Years - 70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
Kathleen M Zackowski, Ph.D., ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT01594853
Organization ID
NA_00045673
Responsible Party
Principal Investigator
Study Sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Collaborators
European Leukodystrophy Association
Study Sponsor
Kathleen M Zackowski, Ph.D., Principal Investigator, Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Verification Date
December 2017